High-sensitivity C-reactive protein levels and cancer mortality

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 2076-2086

  Ko, Young Jin ^a   Kwon, Young Min ^a   Kim, KyaeHyung ^a   Choi, Ho Chun ^a   Chun, SoHyun ^a   Yoon, Hyung Jin ^b   Goh, Eurah ^c   Cho, Belong ^a   Park, Minseon ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CANCER MORTALITY; FEMALE; FOLLOW UP; HUMAN; KOREA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; TERTIARY HEALTH CARE;

C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84869224653     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0611     Document Type: Article

References (43)

1. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48. (Pubitemid 12013176)
2. Burtis C, Ashwood E, Bruns D. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. St. Louis: Elsevier Saunders; 2006.
3. Baune BT, Rothermundt M, Ladwig KH, Meisinger C, Berger K. Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age (Dordr) 2011;33:209-17.
4. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12. (Pubitemid 29231100)
5. Stork S, Feelders RA, van den Beld AW, Steyerberg EW, Savelkoul HF, Lamberts SW, et al. Prediction of mortality risk in the elderly. Am J Med 2006;119:519-25. (Pubitemid 43795183)
6. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11:1639-43. (Pubitemid 40520804)
7. Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007;16:1155-9. (Pubitemid 46984952)
8. Makita S, Nakamura M, Satoh K, Tanaka F, Onoda T, Kawamura K, et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 2009;204:234-8.
9. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg cohort study, 1984-1998. Clin Chem 2008;54:335-42. (Pubitemid 351302620)
10. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008;54:343-9. (Pubitemid 351302621)
11. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
12. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001;41:64-9. (Pubitemid 34666222)
13. Centers for Disease Control and Prevention [internet]. Atlanta: [cited 2011 Jul 29]. Available from: http://apps.nccd.cdc.gov/uscs/toptencancers.aspx.
14. National Cancer Center [internet]. Goyang: [cited 2011 Jul 29]. Available from: http://www.cancer.go.kr/cms/statics/mortality/index.html.
15. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol 2011;21:161-8.
16. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-41.
17. National Statistical Office [internet]. Seoul, Korea. 2005 Annual report on the cause of death statistics (based on vital registration). [cited 2011 Jul 29]. Available from: http://kostat.go.kr.
18. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8. (Pubitemid 41437845)
19. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006;94:227-30. (Pubitemid 43151540)
20. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23.
21. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-7.
22. Yun EH, Park EY, Lee HY, Kong HJ, Jun JK, Oh JK, et al. Cancer facts & figures 2011 in the Republic of Korea. Gyeonggido: National Cancer Center, Minister for Health & Welfare; 2011; p48.
23. Basso D, Fabris C, Meani A, Del Favero G, Vianello D, Angonese C, et al. C reactive protein in pancreatic cancer and chronic pancreatitis. Ann Clin Res 1988;20:414-6. (Pubitemid 19050949)
24. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-80. (Pubitemid 350022405)
25. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511. (Pubitemid 36158056)
26. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002;136:529-33. (Pubitemid 34252287)
27. Zhang SMM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890-4. (Pubitemid 47073511)
28. Zhang SM, Buring JE, Lee I-M, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005 142:425-32.
29. Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 2000;7:273-81. (Pubitemid 30445958)
30. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med 2003;348:1672-80. (Pubitemid 36459474)
31. Hakama M, Coleman MP, Alexe D-M, Auvinen A. Cancer screening. In: Coleman MP, Alexe D-M, Albreht T, McKee M, editors. Responding to the challenge of cancer in Europe. Slovenia: Institute of Public Health of the Republic of Slovenia; 2008. p.69-92.
32. Karsa LV, Anttila A, Ronco G, Ponti A, Arbyn M, Segnan N, et al. Cancer screening in the European Union Report on the implementation of the Council Recommendation on cancer screening (first report). Lyon: International Agency for Research on Cancer; 2008; p.160.
33. Michalas SP. The Pap test: George N. Papanicolaou (1883-1962). A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 2000;90:135-8. (Pubitemid 30307526)
34. O'Loughlin J, Lambert M, Karp I, McGrath J, Gray-Donald K, Barnett TA, et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tob Res 2008;10:525-32. (Pubitemid 351385834)
35. Nanri A, Moore MA, Kono S. Impact of C-reactive protein on disease risk and its relation to dietary factors. Asian Pac J Cancer Prev 2007;8:167-77.
36. Tewari N, Martin-Ucar AE, Black E, Beggs L, Beggs FD, Duffy JP, et al. Nutritional status affects long term survival after lobectomy for lung cancer. Lung Cancer 2007;57:389-94. (Pubitemid 47285422)
37. Jagoe RT, Goodship TH, Gibson GJ. The influence of nutritional status on complications after operations for lung cancer. Ann Thorac Surg 2001;71:936-43. (Pubitemid 32215296)
38. Tovar J, Nilsson A, Johansson M, Ekesbo R, Aberg AM, Johansson U, et al. A diet based on multiple functional concepts improves cardiometabolic risk parameters in healthy subjects. Nutr Metab (Lond) 2012;9:29.
39. Guo CH, Chen PC, Lin KP, Shih MY, Ko WS. Trace metal imbalance associated with oxidative stress and inflammatory status in antihepatitis C virus antibody positive subjects. Environ Toxicol Pharmacol 2012;33:288-96.
40. Cavicchia PP, Steck SE, Hurley TG, Hussey JR, Ma Y, Ockene IS, et al. A new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive protein. J Nutr 2009;139:2365-72.
41. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011;98:268-74.
42. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol 2002;28:396-400.
43. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T. Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 2010;40:440-3.